PubMed:32178765 / 2109-2545 JSONTXT

{"project":"Inflammaging","denotations":[{"id":"T16","span":{"begin":0,"end":436},"obj":"Sentence"},{"id":"T16","span":{"begin":0,"end":436},"obj":"Sentence"}],"text":"The primary endpoint was met: ACR20 at week 24 was achieved by significantly greater proportions of patients in the guselkumab every 4 weeks group (76 [59%] of 128 [95% CI 50-68]) and every 8 weeks group (66 [52%] of 127 [43-61]) than in the placebo group (28 [22%] of 126 [15-30]), with percentage differences versus placebo of 37% (95% CI 26-48) for the every 4 weeks group and 30% (19-41) for the every 8 weeks group (both p\u003c0·0001)."}

{"project":"yaoziqian_800_3","denotations":[{"id":"T14","span":{"begin":116,"end":126},"obj":"CI"},{"id":"T15","span":{"begin":242,"end":249},"obj":"CI"},{"id":"T16","span":{"begin":318,"end":325},"obj":"CI"}],"text":"The primary endpoint was met: ACR20 at week 24 was achieved by significantly greater proportions of patients in the guselkumab every 4 weeks group (76 [59%] of 128 [95% CI 50-68]) and every 8 weeks group (66 [52%] of 127 [43-61]) than in the placebo group (28 [22%] of 126 [15-30]), with percentage differences versus placebo of 37% (95% CI 26-48) for the every 4 weeks group and 30% (19-41) for the every 8 weeks group (both p\u003c0·0001)."}

{"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T14","span":{"begin":116,"end":126},"obj":"CI"},{"id":"T22","span":{"begin":242,"end":249},"obj":"CI"},{"id":"T23","span":{"begin":318,"end":325},"obj":"CI"}],"text":"The primary endpoint was met: ACR20 at week 24 was achieved by significantly greater proportions of patients in the guselkumab every 4 weeks group (76 [59%] of 128 [95% CI 50-68]) and every 8 weeks group (66 [52%] of 127 [43-61]) than in the placebo group (28 [22%] of 126 [15-30]), with percentage differences versus placebo of 37% (95% CI 26-48) for the every 4 weeks group and 30% (19-41) for the every 8 weeks group (both p\u003c0·0001)."}